关于道路交通标志的认知模型

道路交通标志作为重要的道路设施,其设计和布置旨在发挥最大的功能和效用。分析了驾驶员对交通标志的感知与认知过程,及对此过程有潜在影响的各种因素,总结出交通标志对驾驶任务的3种干预类型。结合满意决策理论(Satisficing Decision Making)和认知架构理论(Cognitive Architecture),构建出驾驶员对交通标志的认知模型,为交通标志效用评估的相关研究提供理论框架支持,对交通标志的科学设计和布置提供指导。

Traffic sign recognition algorithm based on shape signature and dual-tree complex wavelet transform

A novel traffic sign recognition system is presented in this work. Firstly, the color segmentation and shape classifier based on signature feature of region are used to detect traffic signs in input video sequences. Secondly, traffic sign color-image is preprocessed with gray scaling, and normalized to 64×64 size. Then, image features could be obtained by four levels DT-CWT images. Thirdly, 2DICA and nearest neighbor classifier are united to recognize traffic signs. The whole recognition algorithm is implemented for classification of 50 categories of traffic signs and its recognition accuracy reaches 90%. Comparing image representation DT-CWT with the well-established image representation like template, Gabor, and 2DICA with feature selection techniques such as PCA, LPP, 2DPCA at the same time, the results show that combination method of DT-CWT and 2DICA is useful in traffic signs recognition. Experimental results indicate that the proposed algorithm is robust, effective and accurate.

Translating Chinese Public Signs into English from Context of the Adaptation Theory

Translation of public signs is related to the image of a city. It has aroused more and more concerns in recent years, for translations of these public signs are often totally wrong or inappropriate. Although many translators have pointed out all kind of mistakes, there is no guiding theory in translating public signs. According to the adaptation theory by Jef. Verschuren, the use of language is just to make continuous choices in order to adapt to the needs of communications. This scientific new research angle can explain and guide translation of public signs. The argument of this paper is how to translate Chinese public signs into English from different context. And it will be analyzed from three different ways： linguistic, communicative, dynamic dimensions.

Pancreatic cancer:Translational research aspects and clinical implications

Despite improvements in surgical techniques and adjuvant chemotherapy, the overall mortality rates in pan- creatic cancer have generally remained relatively un-changed and the 5-year survival rate is actually below 2%. This paper will address the importance of achieving an early diagnosis and identifying markers for prog- nosis and response to therapy such as genes, proteins, microP, NAs or epigenetic modifications. However, there are still major hurdles when translating investigational biomarkers into routine clinical practice. Furthermore, novel ways of secondary screening in high-risk individu- als, such as artificial neural networks and modern imaging, will be discussed. Drug resistance is ubiquitous in pancreatic cancer. Several mechanisms of drug resistance have already been revealed, including human equilibrative nucleoside transporter-1 status, multidrug resistance proteins, aberrant signaling pathways, mi-croRNAs, stromal influence, epithelial-mesenchymal transition-type cells and recently the presence of can- cer stem cells/cancer-initiating cells. These factors must be considered when developing more customized types of intervention （＇personalized medicine＇S. In the future, multifunctional nanoparticles that combine a specific targeting agent, an imaging probe, a cell-penetrating agent, a biocompatible polymer and an anti-cancer drug may become valuable for the management of pa- tients with pancreatic cancer.

Real-time routing control design for traffic networks with multi-route choices

This work considers those road networks in which there are multi-route choices for bifurcation-destination(or origin-destination) pairs, and designs a real-time variable message sign(VMS)-based routing control strategy in the model predictive control(MPC) framework. The VMS route recommendation provided by the traffic management authority is directly considered as the control variable, and the routing control model is established, in which a multi-dimensional control vector is introduced to describe the influence of route recommendations on flow distribution. In the MPC framework, a system optimum routing strategy with the constraints regarding drivers' acceptability with recommended routes is designed, which can not only meet the traffic management authority's control requirement but also improve drivers' satisfaction with the route guidance system. The simulation carried out shows that the proposed routing control can effectively mitigate traffic congestion, reduces followers' time delay, and improves drivers' satisfaction with routing control in road networks.

Prostate cancer： the need for biomarkers and new therapeutic targets

Prostate cancer （PCa） incidence and mortality have decreased in recent years. Nonetheless, it remains one of the most prevalent cancers in men, being a disquieting cause of men＇s death worldwide. Changes in many cell signaling pathways have a predominant role in the onset, development, and progression of the disease. These include prominent pathways involved in the growth, apoptosis, and angiogenesis of the normal prostate gland, such as an- drogen and estrogen signaling, and other growth factor signaling pathways. Understanding the foundations of PCa is leading to the discovery of key molecules that could be used to improve patient management. The ideal scenario would be to have a panel of molecules, preferably detectable in body fluids, that are specific and sensitive biomarkers for PCa In the early stages, androgen deprivation is the gold standard therapy. However, as the cancer progresses, it even- tually becomes independent of androgens, and hormonal therapy fails. For this reason, androgen-independent PCa is still a major therapeutic challenge. By disrupting specific protein interactions or manipulating the expression of some key molecules, it might be possible to regulate tumor growth and metastasis formation, avoiding the systemic side effects of current therapies. Clinical trials are already underway to assess the efficacy of molecules specially designed to target key proteins or protein interactions. In this review, we address that recent progress made towards under- standing PCa development and the molecular pathways underlying this pathology. We also discuss relevant molecular markers for the management of PCa and new therapeutic challenges.